Illumina Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 300 shares of the company’s stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the completion of the transaction, the director now directly owns 6,924 shares in the company, valued at $1,206,783.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Illumina Inc. (NASDAQ:ILMN) traded up 1.51% during mid-day trading on Wednesday, hitting $178.45. 779,332 shares of the stock traded hands. The firm has a market cap of $26.16 billion, a P/E ratio of 61.11 and a beta of 0.73. Illumina Inc. has a 52 week low of $127.10 and a 52 week high of $196.47. The firm’s 50-day moving average price is $170.03 and its 200-day moving average price is $153.91.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The firm earned $600 million during the quarter, compared to analysts’ expectations of $31.91 million. During the same period in the prior year, the company posted $0.80 EPS. The company’s revenue was up 11.3% on a year-over-year basis. On average, equities analysts forecast that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/robert-s-epstein-sells-300-shares-of-illumina-inc-ilmn-stock.html

Large investors have recently bought and sold shares of the company. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares during the period. Fuller & Thaler Asset Management Inc. purchased a new stake in Illumina during the second quarter valued at $112,000. Ropes Wealth Advisors LLC boosted its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares during the period. Finally, Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares during the period. Institutional investors own 95.22% of the company’s stock.

A number of research firms have recently weighed in on ILMN. Citigroup Inc. upped their price target on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, September 12th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a research note on Friday, August 26th. CL King downgraded shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Argus increased their target price on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Finally, Vetr raised shares of Illumina from a “strong sell” rating to a “sell” rating and set a $155.68 target price on the stock in a research report on Monday, August 1st. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $163.07.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.